October 18, 2017 / 1:15 PM / 8 months ago

BRIEF-Radius Health receives FDA fast track designation for elacestrant

* Radius health receives fda fast track designation for elacestrant (rad1901)

* Radius health - ‍plans to initiate phase 2 clinical study of elacestrant as a third-line therapy for women with er+ and her2- breast cancer early in 2018​

* Radius health inc - ‍expect to enroll first patient in phase 2 study in early 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below